Report Overview:
The global Monkeypox Vaccine market pertains to the development, production, distribution, and sale of vaccines designed to protect individuals from the monkeypox virus. Monkeypox is a viral zoonosis (a virus transmitted to humans from animals) with symptoms that resemble smallpox but are less severe. It is primarily transmitted from animals to humans and can spread through direct contact with infected individuals or animals, making vaccination a crucial public health measure. With the eradication of smallpox, monkeypox has emerged as the most significant orthopoxvirus, especially in regions such as Central and West Africa. However, due to its rising incidence, there has been increased demand for vaccines to combat the virus and prevent further outbreaks.
These vaccines are being developed using various techniques such as DNA-based vaccines, non-replicating viral vector vaccines, protein subunit vaccines, and RNA vaccines, each aiming to induce immunity against the monkeypox virus. The increasing incidence of monkeypox cases, particularly in non-endemic regions, has elevated the importance of these vaccines globally.
Market Value:
The Monkeypox Vaccine market was valued at USD 5 million in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 5.60% from 2024 to 2032, reaching an estimated value of USD 7.73 million by 2032.
By Types:
• DNA
• Non-replicating Viral Vector
• Protein Subunit
• RNA
By Applications: Adult
Child
Key players include:
• Bavarian Nordic
• Including or Excluding key companies relevant to your analysis.
